Pharsight

Advair Hfa generic

Advair Hfa is an aerosol inhaler owned by Glaxo Group Ltd. Its active constituents contain Fluticasone Propionate and Salmeterol Xinafoate which make it effective in treating various respiratory conditions. The drug was first authorized for market use on 08 June, 2006 and has held a total of 4 drug patents, two of which have already expired.

When will Advair Hfa generic be available?

The generics of Advair Hfa are possible to be released after the expiry date of the last patent, which is on 26 August, 2026. This release date accounts for a pediatric extension that was added to one of the patents, allowing for an extension of 6 months.

Advair Hfa uses

Advair Hfa, containing Fluticasone Propionate and Salmeterol Xinafoate, is used primarily in the management of asthma and chronic obstructive pulmonary disease (COPD). It works by reducing inflammation and relaxing muscles in the airways to improve breathing.

Advair Hfa patent expiration

Advair Hfa is a metered dose inhaler with a total of 4 patents. Two of which have already expired, and the last one is expected to expire on the 26th of August, 2026 due to a pediatric extension. The generic of Advair Hfa is anticipated to be released shortly after. Below are the details of the patent:

Advair Hfa dosage

Want to ask something?